This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lawrence, W. F. Articles by Mandelblatt, J. S. Search for Related Content PubMed PubMed Citation Articles by Lawrence, W. F. Articles by Mandelblatt, J. S.

Cost of Genetic Counseling and Testing for BRCA1 and BRCA2 Breast Cancer Susceptibility Mutations¹

Cancer Clinical and Economic Outcomes Core [W. F. L., W. L., J. S. M.], Division of Cancer Prevention and Control, and Cancer Genetics [B. N. P., C. I., C. L.], Lombardi Cancer Center, Georgetown University, Washington, D. C. 20007

Counseling and predictive testing are now available for the recently isolated BRCA1 and BRCA2 breast cancer susceptibility genes. We examined the societal costs of providing this counseling and testing to women at risk of having a breast cancer susceptibility mutation. Genetic counselors in a research program prospectively monitored the time necessary to provide counseling and results disclosure. A time-motion study was used to determine time spent on phone calls, preparation, and documentation for counseling. Study participants were surveyed to determine travel time and need for dependent care during counseling. The test cost was calculated using the charge for full BRCA1/2 gene sequencing (Myriad Genetics, Inc.) multiplied by a Medicare-based cost-to-charge ratio. Counselors spent an average of 4.2 h providing genetic counseling for women at risk of having a susceptibility mutation. Genetic counseling without testing cost on average $213, whereas counseling, testing, and disclosure of results totaled $2057. A brief physician-based counseling instead of genetic counselor-based counseling would produce only small reductions in total costs. Providing counseling and testing to the study population averaged $8034 per mutation found. The cost of testing and counseling exceeded $2000. The counseling portion of the cost comprised only 16% of the total cost, with the remainder representing costs associated with testing; thus, alternatives to full genetic counseling that shorten counseling time are unlikely to have a large impact on the overall cost of counseling and testing. The cost of detecting a mutation within a population of women is highly dependent on the prevalence of the mutation in the population.

This article has been cited by other articles:

				J. S. Mandelblatt, J. Cullen, W. F. Lawrence, A. L. Stanton, B. Yi, L. Kwan, and P. A. Ganz Economic Evaluation Alongside a Clinical Trial of Psycho-Educational Interventions to Improve Adjustment to Survivorship Among Patients With Breast Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1684 - 1690. [Abstract] [Full Text] [PDF]

				D. E. Jonas, L. B. Russell, R. S. Sandler, J. Chou, and M. Pignone Value of Patient Time Invested in the Colonoscopy Screening Process: Time Requirements for Colonoscopy Study Med Decis Making, February 1, 2008; 28(1): 56 - 65. [Abstract] [PDF]

				K. D. Graves, L. M. Moss, C. L. Jasper, T. A. DeMarco, B. N. Peshkin, C. Isaacs, and M. D. Schwartz Predictors of Enrollment into a Familial Cancer Registry by Individuals at High Risk for BRCA1/2 Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2763 - 2767. [Abstract] [Full Text] [PDF]

				K. Anderson, J. S. Jacobson, D. F. Heitjan, J. G. Zivin, D. Hershman, A. I. Neugut, and V. R. Grann Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med, March 21, 2006; 144(6): 397 - 406. [Abstract] [Full Text] [PDF]

				J. S. Mandelblatt, W. F. Lawrence, J. Cullen, A. L. Stanton, J. L. Krupnick, L. Kwan, and P. A. Ganz Patterns of Care in Early-Stage Breast Cancer Survivors in the First Year After Cessation of Active Treatment J. Clin. Oncol., January 1, 2006; 24(1): 77 - 84. [Abstract] [Full Text] [PDF]

				D. I. Shalowitz and F. G. Miller Disclosing Individual Results of Clinical Research: Implications of Respect for Participants JAMA, August 10, 2005; 294(6): 737 - 740. [Full Text] [PDF]

				A. S. Whittemore, G. Gong, E. M. John, V. McGuire, F. P. Li, K. L. Ostrow, R. DiCioccio, A. Felberg, and D. W. West Prevalence of BRCA1 Mutation Carriers among U.S. Non-Hispanic Whites Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2078 - 2083. [Abstract] [Full Text] [PDF]